

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-Hodgkin's lymphoma (NHL)	EPH receptor A7 (EPHA7)	<p>Mouse and tissue culture studies suggest soluble EPHA7 could help treat NHL. In tumors from 332 follicular lymphoma patients, EPHA7 was not expressed in 72% of the samples, suggesting that variants of the protein could have tumor-suppressive properties. In a mouse model of Burkitt's lymphoma, a soluble splice variant of Epha7 caused tumor regression, whereas vehicle did not. Next steps include defining the minimal length of an EPHA7 peptide that has activity.</p> <p><i>SciBX</i> 4(44); doi:10.1038/scibx.2011.1232 Published online Nov. 10, 2011</p>	Patent application filed; available for licensing	<p>Oricchio, E. <i>et al. Cell</i>; published online Oct. 28, 2011; doi:10.1016/j.cell.2011.09.035 Contact: Hans-Guido Wendel, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: wendelh@mskcc.org</p>